Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BHC stock price vs QLYS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QLYS's multiple
Needs QLYS P/E.
Implied fair value · at BHC's multiple
Needs BHC P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Bausch Health Companies Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Qualys, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-37.98x
0.17x
Net debt / EBITDA
Leverage against operating earnings
8.15x
-0.62x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$250.26M
Total debt
Interest-bearing obligations outstanding
$21.04B
$95.20M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
CrowdStrike Holdings, Inc.
BHC vs CRWD
Okta, Inc.
BHC vs OKTA
Gen Digital Inc.
BHC vs GEN
Palo Alto Networks Inc
BHC vs PANW
Fortinet, Inc.
BHC vs FTNT
Zscaler, Inc.
BHC vs ZS
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
